Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Urologic Oncology|December 17, 2014
Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancerFerenc G Rick, Andrew V Schally
The Prostate|April 28, 2017
Discovery of LHRH and development of LHRH analogs for prostate cancer treatmentAndrew V Schally, Norman L Block, Ferenc G Rick
Oncotargets and Therapy|April 27, 2013
An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancerFerenc G Rick, Norman L Block, Andrew V Schally
Asian Journal of Andrology|June 27, 2015
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormonesAndrew V Schally, Norman L Block, Ferenc G Rick
Expert Opinion on Pharmacotherapy|August 30, 2013
Agonists of luteinizing hormone-releasing hormone in prostate cancerFerenc G Rick, Norman L Block, Andrew V Schally
Cell Cycle (Georgetown, Tex.)|February 5, 2015
Potentiating effects of GHRH analogs on the response to chemotherapyAndrew V Schally, Roberto Perez, Norman L Block, et al.
Expert Opinion on Therapeutic Targets|January 21, 2015
Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancerPetra Popovics, Daniel E Frigo, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2017
Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cellsPetra Popovics, Andrew V Schally, Luis Salgueiro, et al.
The Prostate|May 23, 2018
Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitisPetra Popovics, Renzhi Cai, Wei Sha, et al.
Oncotarget|July 5, 2014
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levelsPetra Popovics, Andrew V Schally, Luca Szalontay, et al.
Pageof 6